Chimeric antigen receptor (CAR) T‑cell therapy has rapidly evolved into one of the most competitive and complex areas of biotech innovation. As such, an effective IP strategy for CAR-T is now beyond commercially critical.
The key reason an IP strategy for CAR-T is so essential for companies operating in this space is that it will protect your innovation and allow you to best manage third-party rights. Effective protection requires a layered approach that spans the CAR construct itself, encoding sequences, delivery systems, the engineered cell product, medical uses, and formulations.
However, creating an effective IP strategy for CAR-T also requires companies to carefully consider and factor in freedom‑to‑operate (FTO) constraints, potential regulatory issues and lifecycle development.
